Differentiating Hedgehog Pathway Inhibitors in Locally Advanced Basal Cell Carcinoma

Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.

Although hedgehog pathway inhibitors are considered first-line systemic therapy for locally advanced disease, surgical fatigue and patient preference may warrant earlier discussion of oral treatment than current practice patterns reflect.